Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells
5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to...
Saved in:
Published in | Archives of pharmacal research Vol. 38; no. 2; pp. 239 - 248 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Heidelberg
Pharmaceutical Society of Korea
01.02.2015
대한약학회 |
Subjects | |
Online Access | Get full text |
ISSN | 0253-6269 1976-3786 1976-3786 |
DOI | 10.1007/s12272-014-0528-9 |
Cover
Abstract | 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions. |
---|---|
AbstractList | 5-FU is an anticancer drug that is widely used totreat cancers, including colorectal cancer (CRC); however,chemoresistance to 5-FU remains an important problem tobe resolved. The role of microRNAs (miRs) in chemosensitivityhas recently been studied in the development oftherapeutic strategies to overcome drug resistance. Here, wefocused on miR-96, which has been reported to demonstratechemosensitivity. We investigated whether 5-FU sensitivitymay be modulated by miR-96 in monolayer cells and whetherthis relationship also applies for drug resistance in 3Dtumor spheroids (TSs). When the level of miR-96 increased,the expression of the anti-apoptotic regulator XIAP and p53stability regulator UBE2N decreased, resulting in increasedapoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpressionof XIAP and UBE2N, yet only minimal change wasinduced in apoptosis. Nonetheless, luciferase assay failed toshow direct interactions between miR-96 and these genes. InTSs, 5-FU resistance corresponded to a significantly lowerlevel of miR-96, however only XIAP, not UBE2N, was upregulateddemonstrating partial agreement with the 2Dcondition regarding target expression. Overall, these resultssuggest that miR-96 may modulate 5-FU sensitivity in CRCcells by promoting apoptosis; however, differential expressionof target genes in TSs warrants further studies on the5-FU resistance mechanism under 3D conditions. KCI Citation Count: 35 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions. 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions.5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions. 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions. |
Author | Kim, Sun-Ah Kim, Injung Lee, Eun Kyung Yoon, Sungjoo Kim Kuh, Hyo-Jeong |
Author_xml | – sequence: 1 givenname: Sun-Ah surname: Kim fullname: Kim, Sun-Ah organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea – sequence: 2 givenname: Injung surname: Kim fullname: Kim, Injung organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea – sequence: 3 givenname: Sungjoo Kim surname: Yoon fullname: Yoon, Sungjoo Kim organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea, Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea – sequence: 4 givenname: Eun Kyung surname: Lee fullname: Lee, Eun Kyung organization: Department of Biochemistry, College of Medicine, The Catholic University of Korea, Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea – sequence: 5 givenname: Hyo-Jeong surname: Kuh fullname: Kuh, Hyo-Jeong email: hkuh@catholic.ac.kr organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea, Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25502560$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001962657$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNqFkT1v1TAYhS1URG8LP4AFeYTB4I-8jj1eVXxcqQKpKrPlOE5xm9jFTpDuv8dp2oWhTO_g5xxZ5zlDJzFFj9BbRj8ySttPhXHeckJZQyhwRfQLtGO6lUS0Sp6gHeUgiORSn6KzUm4pFRIAXqFTDlDfJN2h_hD7kL2b8ZT6ZbRzSBGnARcfS5jDnzAf8ZwwkGFcUk5Lti6MuDviKbicrr7viZY4RPxrmWzELo1pLbMjdjY6n7Hz41heo5eDHYt_83jP0c8vn68vvpHLH18PF_tL4pqmmYmSqus91cp7atXAdMddC06DHqTWEjylnQXZN50GJT1TqpOib3vGfdM3Qopz9GHrjXkwdy6YZMPDvUnmLpv91fXBMCZkC1DZ9xt7n9PvxZfZTKGsv7XRp6UY1goBVOhG_R-VwBsQFHRF3z2iSzf53tznMNl8NE-DV6DdgLpeKdkPxoX5YfU52zAaRs2q1mxqTVVrVrVmrWb_JJ_Kn8vwLVMqG298NrdVYawOngn9BQTPs8I |
CitedBy_id | crossref_primary_10_2174_1570180818666210930161618 crossref_primary_10_20517_cdr_2024_167 crossref_primary_10_3390_cancers10110440 crossref_primary_10_1016_j_mam_2019_04_002 crossref_primary_10_1016_j_cca_2020_05_012 crossref_primary_10_1016_j_prp_2023_154701 crossref_primary_10_1186_s13046_017_0654_6 crossref_primary_10_1016_j_adcanc_2022_100082 crossref_primary_10_3892_or_2016_4810 crossref_primary_10_1039_C6LC00526H crossref_primary_10_3390_ijms21093233 crossref_primary_10_3390_biomedicines8120530 crossref_primary_10_3389_fonc_2018_00226 crossref_primary_10_3389_fonc_2018_00327 crossref_primary_10_1177_1758835920947342 crossref_primary_10_1186_s13148_018_0587_8 crossref_primary_10_3390_cancers13040624 crossref_primary_10_1186_s13046_020_01731_7 crossref_primary_10_3892_mco_2018_1578 crossref_primary_10_3389_fgene_2019_01245 crossref_primary_10_1016_j_bcp_2021_114409 crossref_primary_10_1111_cpr_12202 crossref_primary_10_1002_jcp_27221 crossref_primary_10_3390_cancers16183183 crossref_primary_10_4251_wjgo_v12_i9_942 crossref_primary_10_1016_j_humimm_2024_111221 crossref_primary_10_1016_j_biopha_2017_11_046 crossref_primary_10_3892_etm_2017_4021 crossref_primary_10_1016_j_semcancer_2022_05_012 crossref_primary_10_3390_biomedicines9121818 crossref_primary_10_1155_2016_5874127 crossref_primary_10_2174_1386207325666220909104803 crossref_primary_10_1177_1010428317697553 crossref_primary_10_2174_1389557523666230825144150 crossref_primary_10_3390_genes8030095 crossref_primary_10_1016_j_biopha_2017_08_084 crossref_primary_10_3390_molecules27196608 crossref_primary_10_3390_ijms19092791 crossref_primary_10_1007_s13105_024_01053_8 crossref_primary_10_3390_ijms21155353 |
Cites_doi | 10.1038/nrc1893 10.1074/jbc.M109.031427 10.1128/MCB.01156-06 10.1016/j.molonc.2013.09.004 10.1371/journal.pone.0015797 10.1007/s12253-013-9695-0 10.1371/journal.pone.0062630 10.1038/cddis.2014.54 10.1186/1476-4598-5-24 10.1038/nrg2634 10.1177/1087057107306839 10.1016/S1097-2765(01)00341-0 10.1158/0008-5472.CAN-12-0103 10.1038/onc.2013.204 10.1007/s12272-009-1614-2 10.1158/0008-5472.CAN-09-4531 10.1371/journal.pone.0072400 10.1111/j.1349-7006.2009.01112.x 10.1038/sj.cdd.4401826 10.1371/journal.pone.0073345 10.1158/1078-0432.CCR-10-1664 10.1093/nar/gkt1275 10.1158/1078-0432.CCR-04-2223 10.1038/sj.embor.7400795 10.1200/JCO.2009.21.8172 10.1371/journal.pone.0034150 10.1093/jnci/djj306 10.1093/jnci/djm135 10.1158/0008-5472.CAN-12-3308 10.1002/ijc.20401 10.3390/molecules13081551 10.1016/j.canlet.2010.10.015 10.1038/nprot.2006.179 10.1097/00001813-200409000-00011 10.1158/0008-5472.CAN-09-1298 10.1073/pnas.90.8.3294 10.4062/biomolther.2010.18.4.375 10.3892/ol.2012.714 10.3892/ol.2012.775 10.3892/or.2012.2138 10.18632/oncotarget.2200 10.3892/or.2014.3337 |
ContentType | Journal Article |
Copyright | The Pharmaceutical Society of Korea 2014 |
Copyright_xml | – notice: The Pharmaceutical Society of Korea 2014 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 ACYCR |
DOI | 10.1007/s12272-014-0528-9 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic AGRICOLA |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1976-3786 |
EndPage | 248 |
ExternalDocumentID | oai_kci_go_kr_ARTI_1136755 25502560 10_1007_s12272_014_0528_9 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .UV .VR 06C 06D 0R~ 0VY 1N0 2.D 203 23N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2WC 2~H 30V 3SX 4.4 406 408 40D 40E 53G 5GY 5VS 67N 67Z 6J9 6NX 8TC 8UJ 95- 95. 95~ 96X 9ZL AAAVM AABHQ AACDK AAHBH AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACREN ACSNA ACUDM ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFGCZ AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BGNMA C1A CAG COF CS3 CSCUP DDRTE DNIVK DPUIP EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH KVFHK LLZTM M4Y MA- MZR N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P2P PF0 PT4 PT5 QOK QOR QOS R89 R9I RHV RNI RNS ROL RPX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SCLPG SDE SDH SHX SISQX SJN SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T16 TEORI TSG TSK TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK6 WK8 YLTOR Z45 Z7U Z7V Z7W Z83 Z87 Z8O Z8P Z8Q Z91 ZMTXR ZOVNA ZZE ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION ABRTQ CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 AABYN AAFGU AAKSU AAPBV AAYFA ABFGW ABKAS ACBMV ACBRV ACBYP ACIGE ACIPQ ACTTH ACVWB ACWMK ACYCR ADMDM ADOXG AEEQQ AEFTE AESTI AEVTX AFAFS AFNRJ AGGBP AGKHE AIMYW AJDOV AKQUC UNUBA Z7X |
ID | FETCH-LOGICAL-c444t-868bde098ee0a8f19b2c75c959f69965e00ba56d4b9586e188b63d7d12e4d4363 |
IEDL.DBID | U2A |
ISSN | 0253-6269 1976-3786 |
IngestDate | Tue Nov 21 21:33:46 EST 2023 Mon Jul 21 09:21:01 EDT 2025 Fri Sep 05 11:32:22 EDT 2025 Mon Jul 21 06:03:38 EDT 2025 Thu Apr 24 23:06:39 EDT 2025 Tue Jul 01 03:46:52 EDT 2025 Fri Feb 21 02:37:03 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | UBE2N MicroRNA-96 XIAP Drug resistance 5-FU Apoptosis |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c444t-868bde098ee0a8f19b2c75c959f69965e00ba56d4b9586e188b63d7d12e4d4363 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000010.2015.38.2.012 |
PMID | 25502560 |
PQID | 1652453059 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1136755 proquest_miscellaneous_1733503948 proquest_miscellaneous_1652453059 pubmed_primary_25502560 crossref_citationtrail_10_1007_s12272_014_0528_9 crossref_primary_10_1007_s12272_014_0528_9 springer_journals_10_1007_s12272_014_0528_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-02-01 |
PublicationDateYYYYMMDD | 2015-02-01 |
PublicationDate_xml | – month: 02 year: 2015 text: 2015-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Heidelberg |
PublicationPlace_xml | – name: Heidelberg – name: Korea (South) |
PublicationTitle | Archives of pharmacal research |
PublicationTitleAbbrev | Arch. Pharm. Res |
PublicationTitleAlternate | Arch Pharm Res |
PublicationYear | 2015 |
Publisher | Pharmaceutical Society of Korea 대한약학회 |
Publisher_xml | – name: Pharmaceutical Society of Korea – name: 대한약학회 |
References | Zhang, Yin, Xu, Chen (CR43) 2008; 13 Hamfjord, Stangeland, Hughes, Skrede, Tveit, Ikdahl, Kure (CR12) 2012; 7 Karasawa, Miura, Fujibuchi, Ishida, Kaneko, Kinouchi, Okabe, Ando, Murata, Sasaki, Takami, Yamamura, Shibata, Sasaki (CR14) 2009; 100 Arlt, Muerkoster, Schafer (CR1) 2013; 332 Chen, Xia, Xue, Ye (CR3) 2012; 5 Croce (CR5) 2009; 10 Laine, Topisirovic, Zhai, Reed, Borden, Ronai (CR18) 2006; 26 Manoochehri, Karbasi, Bandehpour, Kazemi (CR22) 2014; 20 Vichai, Kirtikara (CR35) 2006; 1 Xu, Qian, Deng, Cai, Tang, Wang, Zhang, Cai (CR39) 2012; 4 CR17 CR37 Lin, Dai, Xiong, Zhao, Chen, Yu, Li, Wang, Song (CR21) 2010; 5 Friedrich, Eder, Castaneda, Doss, Huber, Ebner, Kunz-Schughart (CR8) 2007; 12 Haflidadottir, Larne, Martin, Persson, Edsjo, Bjartell, Ceder (CR11) 2013; 8 Guttilla, White (CR10) 2009; 284 Mikhail, Eetezadi, Allen (CR24) 2013; 8 Broker, Kruyt, Giaccone (CR2) 2005; 11 Suzuki, Imai, Nakayama, Takahashi, Takio, Takahashi (CR31) 2001; 8 Wang, Huang, Calses, Kemp, Taniguchi (CR36) 2012; 72 Zhang, Pickard, Jenei, Bullock, Bruce, Mitter, Kelly, Paraskeva, Strefford, Primrose, Thomas, Packham, Mirnezami (CR42) 2013; 73 Schimmer, Dalili, Batey, Riedl (CR28) 2006; 13 Zhou, Wan, Spizzo, Ivan, Mathur, Hu, Ye, Lu, Fan, Xia, Calin, Ellis, Lu (CR44) 2014; 8 Mattie, Benz, Bowers, Sensinger, Wong, Scott, Fedele, Ginzinger, Getts, Haqq (CR23) 2006; 5 Schimmer, Estey, Borthakur, Carter, Schiller, Tallman, Altman, Karp, Kassis, Hedley, Brandwein, Xu, Mak, Lacasse, Jacob, Morris, Jolivet, Andreeff (CR29) 2009; 27 Kim, Choi, Kim, Kuh (CR16) 2009; 32 Tredan, Galmarini, Patel, Tannock (CR34) 2007; 99 Eckelman, Salvesen, Scott (CR6) 2006; 7 Schmidt, Kalipciyan, Dornstauder, Rizovski, Steger, Sedivy, Mueller, Mader (CR30) 2004; 112 Minchinton, Tannock (CR25) 2006; 6 Xu, He, Chang, Xu, Jiang, Sun, Lin (CR38) 2013; 29 Kashkar (CR15) 2010; 16 Tang, Zheng, Hu, Zeng, Li, Tucker, Monahan, Resnick, Liu, Ramratnam (CR33) 2014; 42 Yu, Lu, Liu, Meng, Ma, Zhao, Liu, Yu, Chen (CR41) 2010; 70 Lee, Nam, Park, Lee, Min Do, Kuh (CR19) 2014; 32 Ress, Stiegebauer, Winter, Schwarzenbacher, Kiesslich, Lax, Jahn, Deutsch, Bauernhofer, Ling, Samonigg, Gerger, Hoefler, Pichler (CR27) 2014 Hicks, Pruijn, Secomb, Hay, Hsu, Brown, Denny, Dewhirst, Wilson (CR13) 2006; 98 Feng, Yu, Pan, Li, Chen, Zhang, Wang, Yang, Xu, Zhang, Xu (CR7) 2014; 5 Li, Vandenboom, Kong, Wang, Ali, Philip, Sarkar (CR20) 2009; 69 Tanaka, Suzuki, Shibahara, Kunita, Isagawa, Yoshimi, Kurokawa, Miyazono, Aburatani, Ishikawa, Fukayama (CR32) 2014; 33 Guo, Liu, Zhang, Shang, Song (CR9) 2012; 4 Cheng, Fan, Xu, Zhang, Dou, Tang, Zhong, Rojas, Yu, Zhao, Vasudevan, Zhang, Nuchtern, Kim, Chen, Lu, Yang (CR4) 2014; 5 Park, Lee, Kang, Nishio, Saijo, Kuh (CR26) 2004; 15 Yeon, Da No, Lee, Nam, Oh, Lee, Kuh (CR40) 2013; 8 LE Broker (528_CR2) 2005; 11 H Karasawa (528_CR14) 2009; 100 Y Guo (528_CR9) 2012; 4 X Tang (528_CR33) 2014; 42 J Feng (528_CR7) 2014; 5 JK Park (528_CR26) 2004; 15 AD Schimmer (528_CR28) 2006; 13 RX Chen (528_CR3) 2012; 5 WM Schmidt (528_CR30) 2004; 112 Y Li (528_CR20) 2009; 69 J Cheng (528_CR4) 2014; 5 M Manoochehri (528_CR22) 2014; 20 AI Minchinton (528_CR25) 2006; 6 XM Xu (528_CR39) 2012; 4 A Arlt (528_CR1) 2013; 332 AS Mikhail (528_CR24) 2013; 8 IK Guttilla (528_CR10) 2009; 284 BS Haflidadottir (528_CR11) 2013; 8 H Kashkar (528_CR15) 2010; 16 MD Mattie (528_CR23) 2006; 5 M Tanaka (528_CR32) 2014; 33 Y Suzuki (528_CR31) 2001; 8 AD Schimmer (528_CR29) 2009; 27 SE Yeon (528_CR40) 2013; 8 528_CR17 D Xu (528_CR38) 2013; 29 528_CR37 SH Kim (528_CR16) 2009; 32 J Hamfjord (528_CR12) 2012; 7 Y Zhou (528_CR44) 2014; 8 KO Hicks (528_CR13) 2006; 98 S Yu (528_CR41) 2010; 70 J Friedrich (528_CR8) 2007; 12 Y Wang (528_CR36) 2012; 72 H Lin (528_CR21) 2010; 5 A Laine (528_CR18) 2006; 26 N Zhang (528_CR43) 2008; 13 AL Ress (528_CR27) 2014 BP Eckelman (528_CR6) 2006; 7 O Tredan (528_CR34) 2007; 99 V Vichai (528_CR35) 2006; 1 L Zhang (528_CR42) 2013; 73 CM Croce (528_CR5) 2009; 10 SH Lee (528_CR19) 2014; 32 |
References_xml | – volume: 6 start-page: 583 year: 2006 end-page: 592 ident: CR25 article-title: Drug penetration in solid tumours publication-title: Nature Reviews Cancer doi: 10.1038/nrc1893 – volume: 284 start-page: 23204 year: 2009 end-page: 23216 ident: CR10 article-title: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells publication-title: Journal of Biological Chemistry doi: 10.1074/jbc.M109.031427 – volume: 26 start-page: 8901 year: 2006 end-page: 8913 ident: CR18 article-title: Regulation of p53 localization and activity by Ubc13 publication-title: Molecular and Cellular Biology doi: 10.1128/MCB.01156-06 – volume: 5 start-page: 5832 year: 2014 end-page: 5844 ident: CR7 article-title: HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96 publication-title: Oncotarget – volume: 8 start-page: 83 year: 2014 end-page: 92 ident: CR44 article-title: miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase publication-title: Molecular Oncology doi: 10.1016/j.molonc.2013.09.004 – volume: 32 start-page: 1427 year: 2014 end-page: 1434 ident: CR19 article-title: Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model publication-title: Oncology Reports – volume: 5 start-page: e15797 year: 2010 ident: CR21 article-title: Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a publication-title: PLoS One doi: 10.1371/journal.pone.0015797 – volume: 29 start-page: 653 year: 2013 end-page: 661 ident: CR38 article-title: Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells publication-title: Oncology Reports – volume: 20 start-page: 301 year: 2014 end-page: 307 ident: CR22 article-title: Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer publication-title: Pathology & Oncology Research doi: 10.1007/s12253-013-9695-0 – volume: 8 start-page: e62630 year: 2013 ident: CR24 article-title: Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: A comparison of docetaxel-loaded block copolymer micelles and Taxotere(R) publication-title: PLoS One doi: 10.1371/journal.pone.0062630 – ident: CR37 – volume: 5 start-page: 800 year: 2012 end-page: 804 ident: CR3 article-title: Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells publication-title: Molecular Medicine Reports – volume: 5 start-page: e1079 year: 2014 ident: CR4 article-title: A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways publication-title: Cell Death and Disease doi: 10.1038/cddis.2014.54 – volume: 5 start-page: 24 year: 2006 ident: CR23 article-title: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies publication-title: Molecular Cancer doi: 10.1186/1476-4598-5-24 – volume: 10 start-page: 704 year: 2009 end-page: 714 ident: CR5 article-title: Causes and consequences of microRNA dysregulation in cancer publication-title: Nature Reviews Genetics doi: 10.1038/nrg2634 – volume: 4 start-page: 339 year: 2012 end-page: 345 ident: CR39 article-title: Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer publication-title: Oncology Letters – volume: 12 start-page: 925 year: 2007 end-page: 937 ident: CR8 article-title: A reliable tool to determine cell viability in complex 3-d culture: The acid phosphatase assay publication-title: Journal of Biomolecular Screening doi: 10.1177/1087057107306839 – volume: 8 start-page: 613 year: 2001 end-page: 621 ident: CR31 article-title: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death publication-title: Molecular Cell doi: 10.1016/S1097-2765(01)00341-0 – volume: 72 start-page: 4037 year: 2012 end-page: 4046 ident: CR36 article-title: MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-12-0103 – volume: 33 start-page: 2454 year: 2014 end-page: 2463 ident: CR32 article-title: EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis publication-title: Oncogene doi: 10.1038/onc.2013.204 – volume: 32 start-page: 915 year: 2009 end-page: 922 ident: CR16 article-title: Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro publication-title: Arch Pharm Res doi: 10.1007/s12272-009-1614-2 – volume: 70 start-page: 6015 year: 2010 end-page: 6025 ident: CR41 article-title: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-09-4531 – volume: 8 start-page: e72400 year: 2013 ident: CR11 article-title: Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1 publication-title: PLoS One doi: 10.1371/journal.pone.0072400 – volume: 100 start-page: 903 year: 2009 end-page: 913 ident: CR14 article-title: Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells publication-title: Cancer Science doi: 10.1111/j.1349-7006.2009.01112.x – volume: 13 start-page: 179 year: 2006 end-page: 188 ident: CR28 article-title: Targeting XIAP for the treatment of malignancy publication-title: Cell Death and Differentiation doi: 10.1038/sj.cdd.4401826 – volume: 8 start-page: e73345 year: 2013 ident: CR40 article-title: Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model publication-title: PLoS One doi: 10.1371/journal.pone.0073345 – volume: 16 start-page: 4496 year: 2010 end-page: 4502 ident: CR15 article-title: X-linked inhibitor of apoptosis: A chemoresistance factor or a hollow promise publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-10-1664 – volume: 42 start-page: 2988 year: 2014 end-page: 2998 ident: CR33 article-title: Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the beta-Catenin/TCF/LEF-1 pathway in gastric cancer cells publication-title: Nucleic Acids Research doi: 10.1093/nar/gkt1275 – volume: 11 start-page: 3155 year: 2005 end-page: 3162 ident: CR2 article-title: Cell death independent of caspase: A review publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-04-2223 – volume: 7 start-page: 988 year: 2006 end-page: 994 ident: CR6 article-title: Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family publication-title: EMBO Reports doi: 10.1038/sj.embor.7400795 – volume: 4 start-page: 561 year: 2012 end-page: 565 ident: CR9 article-title: miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer publication-title: Oncology Letters – ident: CR17 – volume: 27 start-page: 4741 year: 2009 end-page: 4746 ident: CR29 article-title: Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2009.21.8172 – year: 2014 ident: CR27 article-title: MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients publication-title: Molecular Carcinogenesis – volume: 7 start-page: e34150 year: 2012 ident: CR12 article-title: Differential expression of miRNAs in colorectal cancer: Comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing publication-title: PLoS One doi: 10.1371/journal.pone.0034150 – volume: 98 start-page: 1118 year: 2006 end-page: 1128 ident: CR13 article-title: Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/djj306 – volume: 99 start-page: 1441 year: 2007 end-page: 1454 ident: CR34 article-title: Drug resistance and the solid tumor microenvironment publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/djm135 – volume: 73 start-page: 6435 year: 2013 end-page: 6447 ident: CR42 article-title: miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-12-3308 – volume: 112 start-page: 200 year: 2004 end-page: 212 ident: CR30 article-title: Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling publication-title: International Journal of Cancer doi: 10.1002/ijc.20401 – volume: 13 start-page: 1551 year: 2008 end-page: 1569 ident: CR43 article-title: 5-Fluorouracil: Mechanisms of resistance and reversal strategies publication-title: Molecules doi: 10.3390/molecules13081551 – volume: 332 start-page: 346 year: 2013 end-page: 358 ident: CR1 article-title: Targeting apoptosis pathways in pancreatic cancer publication-title: Cancer Letters doi: 10.1016/j.canlet.2010.10.015 – volume: 1 start-page: 1112 year: 2006 end-page: 1116 ident: CR35 article-title: Sulforhodamine B colorimetric assay for cytotoxicity screening publication-title: Nature Protocols doi: 10.1038/nprot.2006.179 – volume: 15 start-page: 809 year: 2004 end-page: 818 ident: CR26 article-title: Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells publication-title: Anti-Cancer Drugs doi: 10.1097/00001813-200409000-00011 – volume: 69 start-page: 6704 year: 2009 end-page: 6712 ident: CR20 article-title: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-09-1298 – volume: 7 start-page: 988 year: 2006 ident: 528_CR6 publication-title: EMBO Reports doi: 10.1038/sj.embor.7400795 – volume: 99 start-page: 1441 year: 2007 ident: 528_CR34 publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/djm135 – ident: 528_CR17 doi: 10.1073/pnas.90.8.3294 – volume: 5 start-page: 800 year: 2012 ident: 528_CR3 publication-title: Molecular Medicine Reports – ident: 528_CR37 doi: 10.4062/biomolther.2010.18.4.375 – volume: 10 start-page: 704 year: 2009 ident: 528_CR5 publication-title: Nature Reviews Genetics doi: 10.1038/nrg2634 – volume: 98 start-page: 1118 year: 2006 ident: 528_CR13 publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/djj306 – volume: 12 start-page: 925 year: 2007 ident: 528_CR8 publication-title: Journal of Biomolecular Screening doi: 10.1177/1087057107306839 – volume: 5 start-page: e1079 year: 2014 ident: 528_CR4 publication-title: Cell Death and Disease doi: 10.1038/cddis.2014.54 – volume: 69 start-page: 6704 year: 2009 ident: 528_CR20 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-09-1298 – volume: 8 start-page: 613 year: 2001 ident: 528_CR31 publication-title: Molecular Cell doi: 10.1016/S1097-2765(01)00341-0 – volume: 5 start-page: e15797 year: 2010 ident: 528_CR21 publication-title: PLoS One doi: 10.1371/journal.pone.0015797 – volume: 32 start-page: 915 year: 2009 ident: 528_CR16 publication-title: Arch Pharm Res doi: 10.1007/s12272-009-1614-2 – year: 2014 ident: 528_CR27 publication-title: Molecular Carcinogenesis – volume: 332 start-page: 346 year: 2013 ident: 528_CR1 publication-title: Cancer Letters doi: 10.1016/j.canlet.2010.10.015 – volume: 4 start-page: 339 year: 2012 ident: 528_CR39 publication-title: Oncology Letters doi: 10.3892/ol.2012.714 – volume: 4 start-page: 561 year: 2012 ident: 528_CR9 publication-title: Oncology Letters doi: 10.3892/ol.2012.775 – volume: 8 start-page: e73345 year: 2013 ident: 528_CR40 publication-title: PLoS One doi: 10.1371/journal.pone.0073345 – volume: 8 start-page: e62630 year: 2013 ident: 528_CR24 publication-title: PLoS One doi: 10.1371/journal.pone.0062630 – volume: 284 start-page: 23204 year: 2009 ident: 528_CR10 publication-title: Journal of Biological Chemistry doi: 10.1074/jbc.M109.031427 – volume: 29 start-page: 653 year: 2013 ident: 528_CR38 publication-title: Oncology Reports doi: 10.3892/or.2012.2138 – volume: 6 start-page: 583 year: 2006 ident: 528_CR25 publication-title: Nature Reviews Cancer doi: 10.1038/nrc1893 – volume: 72 start-page: 4037 year: 2012 ident: 528_CR36 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-12-0103 – volume: 5 start-page: 5832 year: 2014 ident: 528_CR7 publication-title: Oncotarget doi: 10.18632/oncotarget.2200 – volume: 8 start-page: e72400 year: 2013 ident: 528_CR11 publication-title: PLoS One doi: 10.1371/journal.pone.0072400 – volume: 16 start-page: 4496 year: 2010 ident: 528_CR15 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-10-1664 – volume: 27 start-page: 4741 year: 2009 ident: 528_CR29 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2009.21.8172 – volume: 7 start-page: e34150 year: 2012 ident: 528_CR12 publication-title: PLoS One doi: 10.1371/journal.pone.0034150 – volume: 11 start-page: 3155 year: 2005 ident: 528_CR2 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-04-2223 – volume: 26 start-page: 8901 year: 2006 ident: 528_CR18 publication-title: Molecular and Cellular Biology doi: 10.1128/MCB.01156-06 – volume: 42 start-page: 2988 year: 2014 ident: 528_CR33 publication-title: Nucleic Acids Research doi: 10.1093/nar/gkt1275 – volume: 1 start-page: 1112 year: 2006 ident: 528_CR35 publication-title: Nature Protocols doi: 10.1038/nprot.2006.179 – volume: 33 start-page: 2454 year: 2014 ident: 528_CR32 publication-title: Oncogene doi: 10.1038/onc.2013.204 – volume: 15 start-page: 809 year: 2004 ident: 528_CR26 publication-title: Anti-Cancer Drugs doi: 10.1097/00001813-200409000-00011 – volume: 13 start-page: 1551 year: 2008 ident: 528_CR43 publication-title: Molecules doi: 10.3390/molecules13081551 – volume: 8 start-page: 83 year: 2014 ident: 528_CR44 publication-title: Molecular Oncology doi: 10.1016/j.molonc.2013.09.004 – volume: 20 start-page: 301 year: 2014 ident: 528_CR22 publication-title: Pathology & Oncology Research doi: 10.1007/s12253-013-9695-0 – volume: 32 start-page: 1427 year: 2014 ident: 528_CR19 publication-title: Oncology Reports doi: 10.3892/or.2014.3337 – volume: 13 start-page: 179 year: 2006 ident: 528_CR28 publication-title: Cell Death and Differentiation doi: 10.1038/sj.cdd.4401826 – volume: 112 start-page: 200 year: 2004 ident: 528_CR30 publication-title: International Journal of Cancer doi: 10.1002/ijc.20401 – volume: 70 start-page: 6015 year: 2010 ident: 528_CR41 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-09-4531 – volume: 73 start-page: 6435 year: 2013 ident: 528_CR42 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-12-3308 – volume: 100 start-page: 903 year: 2009 ident: 528_CR14 publication-title: Cancer Science doi: 10.1111/j.1349-7006.2009.01112.x – volume: 5 start-page: 24 year: 2006 ident: 528_CR23 publication-title: Molecular Cancer doi: 10.1186/1476-4598-5-24 |
SSID | ssj0036555 |
Score | 2.2821853 |
Snippet | 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important... 5-FU is an anticancer drug that is widely used totreat cancers, including colorectal cancer (CRC); however,chemoresistance to 5-FU remains an important problem... |
SourceID | nrf proquest pubmed crossref springer |
SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 239 |
SubjectTerms | Antimetabolites, Antineoplastic - pharmacology antineoplastic agents apoptosis Apoptosis - drug effects Apoptosis - genetics Cell Culture Techniques colorectal neoplasms drug resistance Drug Resistance, Neoplasm - genetics Fluorouracil - pharmacology gene expression regulation gene overexpression genes growth retardation HCT116 Cells HT29 Cells Humans luciferase Medicine microRNA MicroRNAs - antagonists & inhibitors MicroRNAs - genetics neoplasm cells Pharmacology/Toxicology Pharmacy Research Article Spheroids, Cellular - drug effects Spheroids, Cellular - pathology Transfection Ubiquitin-Conjugating Enzymes - genetics Up-Regulation X-Linked Inhibitor of Apoptosis Protein - genetics 약학 |
Title | Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells |
URI | https://link.springer.com/article/10.1007/s12272-014-0528-9 https://www.ncbi.nlm.nih.gov/pubmed/25502560 https://www.proquest.com/docview/1652453059 https://www.proquest.com/docview/1733503948 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001962657 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Archives of Pharmacal Research, 2015, 38(2), , pp.239-248 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZNAqWX0qav7SOopeTQRiDrZem4lKRJS0IoWUhPwno4LNnYxd497L_vyI8spWmgJ1_ksdC8vvGMZhD6CFJkGHUlKQodiAheEhdVIMzxaJzRwXc_c07P1PFMfLuUl8M97nasdh9Tkp2l3lx2YyxPZQSCUMlAS7fQjoTQPWnjjE1H88uV7Eadgi_nBNC6GVOZd5H4wxltVU15F878K0fauZ6jJ-jxgBnxtGfyU_QgVrvo4emQFd9F--d9_-n1Ab7YXKdqD_A-Pt90pl4_Q-Gk6l0YvqnDMLcL1yVuUxV7P0YCL2ssSblY1Q18tvDzBXZrfJPK9n6cTYlReF7hbrAfTlQTMdiaT7LT4JQFaJ-j2dHhxZdjMoxZIF4IsSRaaRciNTpGWugyM475XHojTakgGpKRUldIFYQzUquYae0UD3nIWBRBcMVfoO2qruIrhHMhIvMsZLT0onRcSwcIT3OXe6DkzATR8bytH3qQp1EYC7vpnpxYZIFFNrHIwiufbl_51TfguG_xB2CivfZzm9pmp-dVba8bC8HBiU3ja3IpJ-j9yGMLupSOpqhivWptpiQTEiyguWdNzrmk3Ag9QS97AbndF4RnHYScoM-jxNjBJLT_3vTr_1r9Bj0CzCb7wvG3aHvZrOI7wEVLt4d2pl9_fj_c6_ThN3WYA64 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9NAEF7RVAJeOMrRcC4I9YF2K3sv7z5GqCWhTVShVCpPK-9hFCW1q9h5CL-eXR-NgFKpT35Zj8fj2Tk8s98A8MlrkcSRzlCaCouoNQxpxy3CmjippbCm_pkznvDhOf12wS7ac9xl1-3elSRrS7057IZxEtoIKIoY9rt0C2xTn4JHPbA9-Prj5KgzwISzetip9-YE-XhddsXMm4j84Y628mV2U6T5T5W0dj7Hj8G0Y7vpOZkfrip9aH79heh4x_d6Ah61wSgcNNrzFNxz-Q64P27L7Ttg76wBtl4fwOnmnFZ5APfg2Qbyev0M2FHe-EZ4Wdh2IBgsMliG9vhmPgWsCshQtlgVS__Y1MwWUK_hZegH_D4ZIMnhLIf1xEAYqAZinjUTlHIJQ3mhfA7Oj4-mX4aond-ADKW0QoILbV0khXNRKrJYamwSZiSTGfdpFnNRpFPGLdWSCe5iITQnNrExdtRSwskL0MuL3O0CmFDqsME2jjJDM00E0z50FEQnxlPSsg-i7jMq04KbhxkbC7WBZQ5iVl7MKohZ-Vs-X99y1SB73Lb4o9cNNTczFfC4w_VnoeZL5bOOkQpzcRLG-uBDpzrKb9IgmjR3xapUMWeYMm9a5S1rEkJYRCQVffCy0btrvnzeV8emfbDf6ZBqbU35f6Zf3Wn1e_BgOB2fqtPR5OQ1eOgDQ9Z0p78BvWq5cm998FXpd-1m-w2d7CHP |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZNCqGXkqaPbJ9qKTm0EbH1snRc2i7ZtlmWkoXchPUqSzZ2sL2H_feR_MhSmgZ68kUeC81oZuQZfR8AH4MVSZxoj_JcWEStYUg7bhHWxEkthTXtz5yzGT9d0O8X7KLnOa2HbvehJNndaYgoTUVzcm39yfbiG8ZZbCmgKGE47Ngd8DB44zQa-gKPB1dMOGtpT0NcJyhk7nIoa94l4o_AtFNU_q6c8696aRuGJvvgcZ8_wnGn8CfggSsOwN5ZXyE_AEfzDot6cwzPt1er6mN4BOdblOrNU2CnRRfO4FVpew4vWHpYx472jlICNiVkyK_WZRU-m5vlCuoNvIotfL9mYyQ5XBawJfmDUWoUFqZmoh1VMFYE6mdgMfl2_uUU9ZQLyFBKGyS40NYlUjiX5MKnUmOTMSOZ9DycjJhLEp0zbqmWTHCXCqE5sZlNsaOWEk6eg92iLNwhgBmlDhts08Qb6jURTIdsTxCdmSBJyxFIhvVWpscjj7QYK7VFUo4qUkFFKqpIhVc-3b5y3YFx3Df4Q1CiujRLFSG04_N3qS4rFQ4KUxWpbDLGRuD9oGMV9lVcmrxw5bpWKWeYsuAN5T1jMkJYQiQVI_CiM5DbeYWjWptOjsDnwWJU7x7qf0_65X-Nfgf25l8n6ud09uMVeBRSOdb1k78Gu021dm9CutTot-2WuAGyXglJ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Indirect+modulation+of+sensitivity+to+5-fluorouracil+by+microRNA-96+in+human+colorectal+cancer+cells&rft.jtitle=Archives+of+pharmacal+research&rft.au=Kim%2C+Sun-Ah&rft.au=Kim%2C+Injung&rft.au=Yoon%2C+Sungjoo+Kim&rft.au=Lee%2C+Eun+Kyung&rft.date=2015-02-01&rft.issn=1976-3786&rft.eissn=1976-3786&rft.volume=38&rft.issue=2&rft.spage=239&rft_id=info:doi/10.1007%2Fs12272-014-0528-9&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0253-6269&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0253-6269&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0253-6269&client=summon |